NCT01450748View on ClinicalTrials.gov

Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Laryngopharyngeal Reflux
Interventions
DRUG

Sodium alginate

oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks

DRUG

Placebo

matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks

Trial Locations (1)

104

TTY Biopharm Company Limited Taipei Branch, Taipei

All Listed Sponsors
lead

TTY Biopharm

INDUSTRY

NCT01450748 - Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux | Biotech Hunter | Biotech Hunter